Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study by Kok, Marlies M. et al.
C L I N I C A L  R E S E A R C H
CORONARY  INTERVENT IONS E
uroIntervention 2
0
1
5
;1
1
-online publish-ahead-of-print O
ctober 2
0
1
5
 
D
O
I: 1
0
.4
2
4
4
/E
IJY1
5
M
1
0
_0
6
1
© Europa Digital & Publishing 2015. All rights reserved.
*Corresponding author: Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Haaksbergerstraat 55,
7513 ER Enschede, The Netherlands. E-mail: c.vonbirgelen@mst.nl
Patient preference regarding assessment of clinical follow-up 
after percutaneous coronary intervention: the PAPAYA study
Marlies M. Kok1, MD; Clemens von Birgelen1,2*, MD, PhD; Ming Kai Lam1, MD, PhD; 
Marije M. Löwik1, PhD; K. Gert M. van Houwelingen1, MD; Martin G. Stoel1, MD, PhD; 
J. (Hans) W. Louwerenburg1, MD; Frits H.A.F. de Man1, MD, PhD; Marc Hartmann1, MD, PhD;
Carine J.M. Doggen2, PhD; Janine A. van Til2, PhD; Maarten J. IJzerman2, PhD
1. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands; 2. Department of
Health Technology and Services Research, MIRA, Institute for Biomedical Technology and Technical Medicine, University of
Twente, Enschede, The Netherlands
Abstract
Aims: To keep patients in long-term clinical follow-up programmes after percutaneous coronary interven-
tion (PCI), knowledge of the patient-preferred mode for follow-up assessment is crucial. We systematically 
assessed patient preference, and explored potential relationships with age and gender.
Methods and results: In the prospective, observational PAPAYA study (ClinicalTrials.gov: NCT02189070), 
2,566 patients, treated by PCI between June 2008 and May 2012, were invited to participate in a postal 
survey on the patient-preferred mode (postal questionnaire, telephone or e-mail consultation) and frequency 
of follow-up assessment. A total of 1,797 (70.0%) patients responded. The vast majority preferred com-
pleting postal questionnaires (1,248 [69.9%]) as compared to telephone (240 [13.4%]) or e-mail-based 
approaches (227 [12.7%]) (p<0.001). With increasing age, there was a gradual decline in preference for 
e-mail (p<0.001); the youngest patients (≤60 years) preferred e-mail-based follow-up more often than the
oldest (21.1% vs. 3.1%). Nevertheless, 79.9% of the youngest preferred to be approached in ways other
than by e-mail. Women more often preferred approaches other than e-mail (94.1% vs. 87.3%, p<0.001).
Conclusions: Patients showed a distinct preference for completing postal questionnaires rather than being 
approached by telephone or e-mail. Younger patients accepted e-mail-based follow-up more often, but the 
majority of the youngest patients still preferred approaches other than by e-mail. 
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Abbreviations
CABG coronary artery bypass grafting
CAD coronary artery disease
DES drug-eluting stents
MI myocardial infarction
PCI percutaneous coronary intervention
Introduction
The collection of long-term clinical follow-up data after percuta-
neous coronary intervention (PCI) is a key issue of randomised 
studies and of growing interest for routine clinical practice. Such 
data have been shown to be highly relevant, as they can reveal 
an increased risk of very late adverse events1,2. For the validity 
of follow-up, it is important that information is obtained from the 
maximum achievable number of patients. Successful retention of 
patients in programmes that collect follow-up data is crucial but 
remains a challenge, as follow-up rates generally decline over 
time3. In large, well-organised, drug-eluting stent (DES) trials, 
a decline in mortality-corrected follow-up rates has been reported 
(98-100% after one year; 89-96% after five years)4-6. In clinical 
practice, adherence to long-term follow-up programmes may even 
be much lower.
When patients are not required to be physically present for fol-
low-up assessment, information may be gathered from national 
databases, telephone contacts, and web-based or postal surveys. 
Taking the patients’ preference regarding the mode and frequency 
of follow-up into account is likely to enhance adherence to follow-
up. In addition, it is in keeping with the general trend towards per-
sonalised healthcare7.
Easy access to internet and e-mail services (internet use and 
access in The Netherlands is among the highest worldwide, even 
among the elderly)8,9 might facilitate the collection of follow-
up information. So far, the patient-preferred mode of follow-up 
after PCI has not been systematically evaluated. Therefore, in 
the prospective PAPAYA study (PAtient Preference Analysis of 
Yearly follow-up After PCI; ClinicalTrials.gov: NCT02189070), 
we assessed the preferred mode and frequency of follow-up data 
acquisition after PCI.
Methods
PATIENT POPULATION
Between May 2013 and May 2014, we performed the PAPAYA 
study (PAtient Preference Analysis of Yearly follow-up After 
PCI) in a consecutive series of patients who, between June 2008 
and May 2012, had undergone PCI procedures at Thoraxcentrum 
Twente in the setting of two large, randomised clinical trials, 
TWENTE and DUTCH PEERS9,10. These trials were performed to 
compare the safety and efficacy of newer-generation DES in study 
populations with very limited exclusion criteria.
The present study assessed a broad and heterogeneous patient 
population that reflects routine clinical practice at our tertiary PCI 
centre. The characteristics of the participants of the TWENTE and 
DUTCH PEERS trials have been reported in detail10,11. In brief, 
TWENTE examined 1,391 “real-world” patients, of whom the 
majority were treated for acute coronary syndromes, had com-
plex coronary lesions, and met criteria of high procedural risk. 
DUTCH PEERS (TWENTE II) assessed a total of 1,811 all-comer 
patients, of whom the majority were treated at Thoraxcentrum 
Twente. In DUTCH PEERS, the proportions of patients with com-
plex coronary lesions and acute coronary syndrome, in particu-
lar ST-elevation myocardial infarction, were very high, and the 
vast majority of patients had a high procedural risk. The PAPAYA 
study complied with the Declaration of Helsinki for investigation 
in human beings and was approved by the institutional review 
board. All patients had provided written informed consent for par-
ticipation in the trials.
STUDY DESIGN
In the prospective, observational PAPAYA study, patients received 
between May 2013 and May 2014 a single, individually addressed 
letter that contained an invitation to participate in a survey by 
completing an enclosed questionnaire, a brief study description, 
and a prepaid envelope for returning the questionnaire to the study 
centre at Thoraxcentrum Twente. Patients were assured they would 
be contacted only once and would not receive any reminders.
The survey collected information about the patient-preferred 
mode of follow-up assessment (postal questionnaire, telephone, 
or e-mail-based). In addition, patients were asked to indicate the 
one or two least preferred approaches of follow-up assessment, 
the preferred number of follow-up events per year, and the max-
imum acceptable number of questions per assessment. A trans-
lated questionnaire is provided in the supplementary web-based 
material (Online Table 1). Demographics and clinical character-
istics of all invited patients were collected from electronic med-
ical files. The available data allowed comparison of responders 
and non-responders for explorative assessment of potential bias. 
To examine the potential impact of age on preferences, responders 
were divided into four age groups as defined by the (rounded off) 
boundaries of age quartiles, based on all invited patients.
STATISTICAL ANALYSIS
Data were reported as frequencies and percentages for dichot-
omous and categorical variables. Continuous variables were 
expressed as mean±standard deviation (SD). Differences between 
dichotomous and categorical variables were assessed using the 
chi-square and Fisher’s exact tests, as appropriate; for ordinal 
data the linear-by-linear association chi-square test was used. 
Continuous variables were assessed with the Student’s t-test. The 
relationship between age and preference was assessed with nomi-
nal regression analyses. Parameters were considered as potential 
confounders if associations were found with a p-value ≤0.15 in 
univariate analyses. A multivariate nominal regression analysis 
was then used to adjust for potential confounders. All statistical 
tests were two-tailed. P-values <0.05 were considered statistically 
significant. Data analysis was performed with SPSS, version 17 
(SPSS Inc., Chicago, IL, USA).
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Results
RESPONDERS AND NON-RESPONDERS
Of the 2,566 invited patients, 1,797 responded and participated in 
the survey (70.0%). Table 1 displays demographics and clinical 
characteristics of the patients. Responders to the survey were on 
average older (67.5±9.7 vs. 65.2±12.3 years; p<0.001). However, 
women, who represented 27.0% of the invited population and were 
significantly older than men, responded less frequently (456/694 
[65.7%] vs. 1,341/1,872 [71.6%], p=0.004). Diabetics, current 
smokers, and patients with a history of myocardial infarction 
Table 1. Characteristics of the study population.
All invited 
patients 
n=2,566
Responders 
n=1,797 
(70.0%)
Non-
responders 
n=769 
(30.0%)
p-value
Age, yrs 66.8±10.6 67.5±9.7 65.2±12.3 <0.001
Men 1,872 (73.0) 1,341 (74.6) 531 (69.1) 0.004
Body mass index, kg/m2 27.9±4.3 27.7±4.2 28.3±4.5 0.005
Chronic renal failure* 72 (2.8) 46 (2.6) 26 (3.4) 0.24
Hypertension¶ 1,381 (55.3) 992 (56.7) 389 (52.0) 0.03
Hypercholesterolaemia 1,334 (53.5) 948 (54.4) 386 (51.4) 0.17
Current smoker 622 (24.2) 385 (21.4) 237 (30.8) <0.001
Diabetes mellitus (any) 474 (18.5) 296 (16.5) 178 (23.1) <0.001
Prior MI‡ 696 (27.1) 460 (25.6) 236 (30.7) 0.008
Prior PCI 485 (18.9) 303 (16.9) 182 (23.7) <0.001
Prior CABG 252 (9.8) 179 (10.0) 73 (9.5) 0.72
Family history of CAD 1,352 (52.7) 940 (52.3) 412 (53.6) 0.56
Clinical syndrome at presentation 0.42
STEMI 283 (11.0) 191 (10.6) 92 (12.0)
NSTEMI 667 (26.0) 470 (26.2) 197 (25.6)
Unstable angina 424 (16.5) 287 (16.0) 137 (17.8)
Stable angina 1,192 (46.5) 849 (47.2) 343 (44.6)
Number of lesions treated per patient 0.39
One 1,739 (67.8) 1,224 (68.1) 515 (67.0)
Two 641 (25.0) 451 (25.1) 190 (24.7)
Three or more 186 (7.2) 122 (6.8) 64 (8.3)
At least 1 complex lesion 1,990 (77.6) 1,391 (77.4) 599 (77.9) 0.79
Target vessel location
Left main stem 78 (3.0) 53 (2.9) 25 (3.3) 0.68
Left anterior 
descending artery 1,285 (50.1) 906 (50.4) 379 (49.3) 0.60
Left circumflex artery 772 (30.1) 546 (30.4) 226 (29.4) 0.62
Right coronary artery 954 (37.2) 659 (36.7) 295 (38.4) 0.42
Bypass graft 75 (2.9) 58 (3.2) 17 (2.2) 0.16
SYNTAX score 14.0±10.8 13.92±10.7 14.19±10.9 0.56
Values are n (%) or mean±SD. *Chronic renal failure defined by serum creatinine level 
≤130 µmol/l. ¶Left ventricular ejection fraction assessed with ultrasound, magnetic 
resonance imaging, or left ventricular angiography. ‡Prior MI, prior PCI, and prior CABG 
indicate MI or revascularisation procedures that occurred before patients were enrolled in 
one of the randomised trials and thus before they underwent the index PCI procedures of 
the respective randomised trials. CABG: coronary artery bypass grafting; CAD: coronary 
artery disease; MI: myocardial infarction; PCI: percutaneous coronary intervention
(MI) or previous PCI also responded slightly but significantly less 
often. Between responders and non-responders, there was no sig-
nificant difference in lesion characteristics, target vessel location, 
or angiographic SYNTAX score.
PREFERRED APPROACH OF FOLLOW-UP AND 
RELATIONSHIP WITH AGE AND GENDER
The vast majority of all responders preferred completing a postal 
questionnaire (1,248 [69.9%]) rather than being approached via tel-
ephone (240 [13.4%]) or e-mail (227 [12.7%]) (p<0.001, Table 2). 
There was a significant, positive relationship between the pref-
erence for a postal questionnaire and age (Table 3, Figure 1). 
Patients aged 60 years or younger preferred least often the postal 
questionnaire, but this approach was still the favourite option 
of 63.5% of these patients and did not differ between patients 
≤54 years of age versus patients 55-60 years of age (63.8% vs. 
63.4%, p=0.42; threshold of 54 years based on median age of the 
youngest patient quartile).
Table 2. Preference regarding follow-up assessment stratified by 
gender.
All 
responders
(n=1,796)
Gender
p-value
Men (n=1,341) Women (n=455)
Age, yrs 67.5±9.7 66.6±9.6 70.1±9.4 <0.001
Preferred approach <0.001
Questionnaire 1,248 (69.9) 916 (68.8) 332 (73.0)
Telephone 240 (13.4) 165 (12.4) 75 (16.5)
E-mail 227 (12.7) 200 (15.0) 27 (5.9)
No preference 71 (4.0) 50 (3.9) 21 (4.6)
Least preferred approach* <0.001
Questionnaire 205 (8.4) 151 (8.6) 54 (8.0)
Telephone 1,153 (47.3) 883 (50.1) 270 (40.0)
E-mail 1,079 (44.3) 728 (41.3) 351 (52.0)
Preferred number of questions per contact <0.001
0 1 (0.1) 1 (0.1) 0 (0)
<5 237 (13.6) 155 (11.8) 82 (19.0)
6-10 964 (55.3) 711 (54.2) 253 (58.7)
11-15 305 (17.5) 254 (19.4) 51 (11.8)
>15 235 (13.5) 190 (14.5) 45 (10.4)
Preferred number of annual follow-up events 0.06
0x¶ 129 (7.4) 89 (6.9) 40 (9.1)
1x 1,024 (59.0) 748 (57.7) 276 (62.7)
2x 464 (26.7) 365 (28.1) 99 (22.5)
3x 34 (2.0) 26 (2.0) 8 (1.8)
4x 86 (5.0) 69 (5.3) 17 (3.9)
Values are n (%). A few patients did not provide answers to all the survey questions. 
Preferred approach: missing <20; preferred number of questions and preferred number of 
annual FUP events missing 21-60. *Indication of up to two least preferred approaches was 
permitted. ¶Patients preferred follow-up data collection from healthcare providers and 
local residents or national registration offices, but not to be contacted themselves.
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In addition, there was a significant, gradual decrease in the 
preference for e-mail-based follow-up with increasing age. In 
age-based quartiles, the youngest patients (≤60 yrs) preferred the 
e-mail-based follow-up much more often than the oldest (>75 yrs) 
(21.1% vs. 3.1%); nevertheless, 78.9% of the youngest patients 
(31-60 years) still preferred to be approached in ways other than 
by e-mail.
Multivariate analysis showed that age is an independent predic-
tor for preference. Patients in the youngest category (≤60 years) 
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Figure 1. Preferences per age group. A) Preferred method per age 
group. B) Least preferred approach per age group. C) Preferred 
number of annual follow-up moments. p-values for ordinal data were 
calculated with linear-by-linear association of χ2 test.
had a 7.1-fold increased chance of preferring e-mail-based fol-
low-up as compared to the eldest patients (>75 years) (p<0.001). 
Compared to this same group of elderly patients, patients aged 
61-67 years had a 5.7-fold increased chance of preferring e-mail, 
and patients aged 67-75 years had a 2.9-fold increased chance of 
preferring e-mail-based follow-up (p<0.001). Per five years that 
patients were younger, the chance of preferring e-mail-based fol-
low-up increased by 1.3 times.
Women were significantly older than men (70.1±9.4 and 
66.6±9.6, respectively, p<0.001) and less likely to prefer e-mail-
based follow-up (5.9% vs 15.0%, p<0.001). While 18.5% of 
women aged 60 years or younger stated that they preferred e-mail-
based follow-up, this approach was only preferred by 0.7% of 
women older than 75. In addition, 58.5% of these elderly women 
indicated that follow-up via e-mail was their least preferred 
approach (Online Table 2, Figure 2).
With increasing age, there was a growing acceptance of tele-
phone-based follow-up (p<0.001), which overall, and in particu-
lar among younger patients, was the least preferred approach. Of 
the 240 patients who preferred to be contacted by telephone, 227 
(94.6%) reported which time of day (morning, afternoon, or even-
ing) they favoured. The majority (53.3%) preferred to be contacted 
in the morning, while 23.3% favoured the afternoon and 23.3% 
the evening. Younger patients preferred follow-up telephone calls 
to be performed in the evening (43.2% and 31.4% for patients 
≤60 years and 61-67 years, respectively), while older patients (68-
75 years and >75 years) preferred less often to be called in the 
evening (10.3% and 21.3%, respectively, p=0.002).
PREFERRED NUMBER OF YEARLY FOLLOW-UP 
ASSESSMENTS AND NUMBER OF QUESTIONS
The majority of patients (59.0%) preferred a single, yearly 
follow-up moment and 26.7% preferred two (Table 2, 
Figure 1). Patients preferred much less often three or four fol-
low-up moments (7.0%) or no personal follow-up moment at all 
(but data collection from healthcare providers was acceptable) 
(7.4%); the latter was most often preferred by the elderly. Most 
patients (55.3%) preferred a maximum number of six to 10 ques-
tions per assessment.
Discussion
The PAPAYA study shows a distinct preference of PCI patients 
for completing a follow-up postal questionnaire rather than being 
approached by telephone or e-mail (70% versus 13% and 13%, 
respectively). Multivariate nominal regression analysis showed 
that age is an independent predictor for preference. The young-
est patient group (≤60 yrs) preferred e-mail-based follow-up more 
often than the oldest (21% versus 3%), but still almost four out of 
five younger patients preferred follow-up approaches other than 
by e-mail. The gender analysis revealed that in women the accept-
ance of e-mail-based follow-up was lower than in men. However, 
it should be noted that women were on average older than men 
(p<0.001), which may have contributed to their lower acceptance 
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rate of the e-mail-based approach. In the light of the fact that The 
Netherlands is among the top five countries worldwide with the 
highest rates of internet use8 and access – even among the popula-
tion aged 65 years and older9 – the relatively low acceptance rate 
of e-mail-based follow-up in the PAPAYA study is remarkable and 
was certainly not anticipated.
PREVIOUS STUDIES
To the best of our knowledge, PAPAYA is the first study to assess 
patient preference regarding follow-up after PCI. The response by 
70% of the invited patients was high. Characteristics of respond-
ers and non-responders were similar but showed some differences. 
Among responders, there was a slight underrepresentation of dia-
betics and patients with a history of MI or PCI. We speculate that 
this might partly be related to recurrent visits of healthcare pro-
viders that could have resulted in a certain “healthcare overload”. 
Reducing the length of postal and electronic questionnaires has 
previously been shown to increase the response rate significantly12, 
which is consistent with our finding that assessments should not 
exceed six to 10 questions. Although intuitively this may seem to 
be a rather small number of questions for a sufficient assessment 
of follow-up information, this number is consistent with or even 
higher than the approximated number of questions that clinicians 
are able to ask during office visits, considering the high time pres-
sure in current clinical practice.
The Dutch Central Bureau for Statistics has assessed the overall 
availability and use of the internet in the total population: 95% of 
all households have access to the internet9, irrespective of educa-
tional level or level of income. Furthermore, The Netherlands has 
the fourth largest number of internet users (74%) in Europe within 
the population aged 65-75 years.
FOLLOW-UP WITHOUT ANY DIRECT PATIENT CONTACT
Elderly patients are a rapidly growing subpopulation of patients 
that has more comorbidities and an increased procedural mortal-
ity13. It is of the utmost importance to assess these patients in clini-
cal trials and follow-up programmes. PAPAYA has shown that one 
out of eight elderly patients >75 years of age, rather than being 
directly contacted, preferred follow-up data to be collected from 
healthcare providers, pharmacies, and local residents’ or national 
registration offices. In Denmark, such an approach is embraced by 
the SORT OUT series of randomised clinical trials that compared 
Table 3. Preference regarding follow-up assessment in all responders and in age-based groups.
All  
responders
Age groups
≤60 yrs 
(n=420)
61-67 yrs 
(n=458)
68-75 yrs 
(n=536)
>75 yrs 
(n=383)
p-value
Mean age, yrs 54.2±5.1 64.4±1.9 71.4±2.3 80.1±3.5
Preferred approach <0.001
Questionnaire 1,248 (69.9) 265 (63.5) 305 (66.7) 387 (72.9) 291 (76.4)
Telephone 240 (13.4) 42 (10.1) 53 (11.6) 80 (15.1) 65 (17.1)
E-mail 227 (12.7) 88 (21.1) 78 (17.1) 49 (9.2) 12 (3.1)
No preference 71 (4.0) 22 (5.3) 21 (4.6) 15 (2.8) 13 (3.4)
Least preferred approach* <0.001
Questionnaire 205 (8.4) 45 (9.3) 44 (7.4) 75 (9.6) 41 (7.1)
Telephone 1,153 (47.3) 299 (61.8) 305 (51.4) 339 (43.3) 210 (36.4)
E-mail 1,079 (44.3) 140 (28.9) 244 (41.1) 369 (47.1) 326 (56.5)
Preferred number of questions per contact <0.001
0 1 (0.1) 0 (0) 1 (0.2) 0 (0) 0 (0)
<5 236 (13.6) 16 (3.9) 48 (10.7) 83 (16.0) 89 (24.5)
6-10 964 (55.4) 211 (51.3) 246 (54.8) 305 (58.9) 202 (55.6)
11-15 305 (17.5) 113 (27.5) 86 (19.2) 72 (13.9) 34 (9.4)
>15 235 (13.5) 71 (17.3) 68 (15.1) 58 (11.2) 38 (10.5)
Preferred number of annual follow-up events <0.001
0x¶ 129 (7.4) 10 (2.4) 27 (6.0) 47 (9.1) 45 (12.6)
1x 1,024 (59.0) 222 (53.6) 257 (57.4) 332 (64.2) 213 (59.5)
2x 464 (26.7) 137 (33.1) 127 (28.3) 112 (21.7) 88 (24.6)
3x 34 (2.0) 10 (2.4) 13 (2.9) 6 (1.2) 5 (1.4)
4x 86 (5.0) 35 (8.5) 24 (5.4) 20 (3.9) 7 (2.0)
Values are n (%). A few patients did not provide answers to all the survey questions. Preferred approach: missing <20; preferred number of questions 
and preferred number of annual FUP events missing 21-60. *Indication of up to two least preferred approaches was permitted. ¶Patients preferred 
follow-up data collection from healthcare providers and local residents or national registration offices, but not to be contacted themselves.
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DES in a head-to-head fashion14-16. Assessment of the follow-up 
of these trials is based on national administrative population and 
healthcare registries of clinical events and procedures, which are 
used as a standard by the entire Danish health system17. This reg-
istry-based event detection provides a way to perform randomised 
studies that fully resemble routine clinical care. This approach has 
proven to be pragmatic, cost-effective, and may help to facilitate 
long-term follow-up. Nevertheless, patient-triggered event rates 
may be typically lower than the event rates of trials with active 
clinical follow-up. This has previously been suggested to be partly 
attributable to a potential detection bias (e.g., inaccuracy of dis-
charge coding)18. On the other hand, certain symptom-driven end-
points, such as repeat revascularisation, may be lower if patients 
are not directly approached by a research team due to the preven-
tion of recall bias. In addition, it is most likely that patients who 
experience significant symptoms will report this to their general 
practitioner or the referring cardiologist. The findings of PAPAYA 
suggest that a registry-based approach, such as applied in the 
SORT OUT series of trials, will facilitate follow-up assessment in 
populations with predominantly elderly patients.
IMPLICATIONS
In current evidence-based healthcare, there is an increasing demand 
for detailed information on medical procedures and related clini-
cal outcomes that can be obtained either from prospective clinical 
trials or from registries of routine clinical practice19. The PAPAYA 
study shows that the majority of patients still prefer completing 
a postal questionnaire and suggests that e-mail-based follow-up 
may be most useful in populations that are on average younger 
than the PCI patients of the present study. Currently, an individ-
ualised approach to follow-up may be a highly efficient option. 
Clinicians and researchers alike should try to amend their follow-
up methods on their patients’ social background, educational level 
and logistics such as accessibility to the internet. The observed age 
dependence of preference for e-mail-based follow-up suggests that 
this attitude may be linked to socialisation in a computer-friendly 
environment. As an early familiarity with computers and the inter-
net is increasingly prevalent, a significant increase in patients 
who prefer e-mail-based follow-up may be expected in the future.
Limitations
There are some limitations that may have influenced the results of 
this survey. First, we used a postal survey, which might have resulted 
in lower return rates for patients who actually preferred e-mail or 
telephone follow-up. This poses as a limitation, which might have 
resulted in an underrepresentation of patients preferring e-mail or tel-
ephone contact. Second, one may feel that performing this study in 
clinical trial participants is a limitation, mostly because many ran-
domised studies examine selected patient populations. However, 
this was not the case in TWENTE and DUTCH PEERS10,11,20,21. 
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Figure 2. Preferences regarding follow-up assessment of men versus women in age-based groups. A) Preference for questionnaire. 
B) Preference for telephone. C) Preference for e-mail. D) No preference.
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The breadth of these study populations and the high enrolment rates at 
our centre suggest that the findings are valid for PCI patients in gen-
eral. Moreover, the TWENTE and DUTCH PEERS trials used both 
postal questionnaire and telephone-based follow-up, which means 
that many trial participants had experience with both approaches. 
A negative experience with either could have resulted in an overrep-
resentation of patients who preferred e-mail follow-up. Nevertheless, 
in the light of the experience with different methods of follow-up, 
it may be assumed that the participants of the PAPAYA study made 
carefully considered choices that should be taken seriously.
Conclusions
Patients showed a distinct preference for completing a postal ques-
tionnaire rather than being approached by telephone or e-mail. 
Younger patients accepted e-mail-based follow-up more often, but 
the majority of the youngest patients still preferred approaches 
other than by e-mail.
Impact on daily practice
Knowledge of the patient-preferred mode for follow-up assess-
ment is crucial in order to keep patients in long-term clinical 
follow-up programmes after PCI. The PAPAYA study shows 
that the majority of patients still prefer completing a postal 
questionnaire and suggests that e-mail-based follow-up may 
be most useful in populations that are on average younger than 
the population of the present study. The age dependence of the 
preference for e-mail suggests that this preference will increase 
in the future. Currently, an individualised approach may be 
a highly efficient option.
Acknowledgements
We thank Mrs. Renate E. van der Leest (Thoraxcentrum Twente, 
Enschede, The Netherlands) for her conscientious administrative 
work.
Funding
This investigator-initiated study was performed by the Cardiology 
Department of Thoraxcentrum Twente and by CardioResearch 
Enschede, in cooperation with the Department of Health 
Technology and Services Research (HTSR) of the University of 
Twente, Enschede, The Netherlands. The study was performed 
without any extramural funding.
Conflict of interest statement
C. von Birgelen has been consultant to and has received lec-
ture fees or travel expenses from Abbott Vascular, Boston 
Scientific, and Medtronic; he received lecture fees from MSD 
and AstraZeneca. The institution has received research grants, 
provided by Abbott Vascular, Biotronik, Boston Scientific, and 
Medtronic. M. IJzerman is consultant to PANAXEA b.v.; he has 
received payments for lectures from Roche, Pfizer, and Sanofi 
Aventis. The other authors have no conflicts of interest to declare.
References
 1. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, 
Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van 
Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, 
Serruys PW. Early and late coronary stent thrombosis of siroli-
mus-eluting and paclitaxel-eluting stents in routine clinical prac-
tice: data from a large two-institutional cohort study. Lancet. 
2007;369:667-78.
 2. Räber L, Magro M, Stefanini GG, Kalesan B, van 
Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, 
Serruys PW, Windecker S. Very late coronary stent thrombosis of 
a newer-generation everolimus-eluting stent compared with early-
generation drug-eluting stents: a prospective cohort study. 
Circulation. 2012;125:1110-21.
 3. Probstfield JL, Frye RL. Strategies for recruitment and reten-
tion of participants in clinical trials. JAMA. 2011;306:1798-9.
 4. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, 
Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, 
Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van 
Es GA, Meier B, Jüni P. Biolimus-eluting stent with biodegradable 
polymer versus sirolimus-eluting stent with durable polymer for 
coronary revascularisation (LEADERS): a randomised non-inferi-
ority trial. Lancet. 2008;372:1163-73.
 5. Onuma Y, Miquel-Hebert K, Serruys PW; SPIRIT II 
Investigators. Five-year long-term clinical follow-up of the 
XIENCE V everolimus-eluting coronary stent system in the treat-
ment of patients with de novo coronary artery disease: the SPIRIT 
II trial. EuroIntervention. 2013;8:1047-51.
 6. Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, 
Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di 
Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-
Havinga T, van Es GA, Meier B, Jüni P, Windecker S. Improved 
safety and reduction in stent thrombosis associated with biode-
gradable polymer-based biolimus-eluting stents versus durable 
polymer-based sirolimus-eluting stents in patients with coronary 
artery disease: final 5-year report of the LEADERS randomized, 
noninferiority trial. JACC Cardiovasc Interv. 2013;6:777-89.
 7. Tak HJ, Ruhnke GW, Meltzer DO. Association of patient 
preferences for participation in decision making with length of stay 
and costs among hospitalized patients. JAMA Intern Med. 
2013;173:1195-205.
 8. The World Bank. Available at: http://data.worldbank.org/
indicator/IT.NET.USER.P2 (accessed June 15, 2015).
 9. Central Bureau of Statistics (CBS). Available at: http://www.
cbs.nl/nl-NL/menu/themas/vrije-tijd-cultuur/publicaties/artikelen/
archief/2013/2013-4005-wm.htm (accessed June 27, 2015).
 10. von Birgelen C, Basalus MW, Tandjung K, van 
Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, 
Saïd SA, Kleijne MA, Sen H, Löwik MM, van der Palen J, 
Verhorst PM, de Man FH. A randomized controlled trial in sec-
ond-generation zotarolimus-eluting Resolute stents versus 
everolimus-eluting Xience V stents in real-world patients: the 
TWENTE trial. J Am Coll Cardiol. 2012;59:1350-61.
8E
uroIntervention 2
0
1
5
;1
1
-online publish-ahead-of-print O
ctober 2
0
1
5
 11. von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, 
Hautvast RW, van Houwelingen GK, Schramm AR, Gin RM, 
Louwerenburg JW, de Man FH, Stoel MG, Löwik MM, Linssen GC, 
Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, 
Tandjung K. Third-generation zotarolimus-eluting and everolimus-
eluting stents in all-comer patients requiring a percutaneous coro-
nary intervention (DUTCH PEERS): a randomised, single-blind, 
multicentre, non-inferiority trial. Lancet. 2014;383:413-23.
 12. Edwards PJ, Roberts I, Clarke J, Diguiseppi C, Wentz R, 
Kwan I, Cooper R, Felix LM, Pratap S. Methods to increase 
response to postal and electronic questionnaires. Cochrane 
Database Syst Rev. 2009;8:MR000008.
 13. Pfisterer M; Trial of Invasive versus Medical therapy in 
Elderly patients Investigators. Long-term outcome in elderly 
patients with chronic angina managed invasively versus by opti-
mized medical therapy: four-year follow-up of the randomized 
Trial of Invasive versus Medical therapy in Elderly patients (TIME). 
Circulation. 2004;110:1213-8.
 14. Galloe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, 
Hansen PR, Bligaard N, Saunamäki K, Junker A, Aarøe J, 
Abildgaard U, Ravkilde J, Engstrøm T, Jensen JS, Andersen HR, 
Bøtker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, 
Abildstrøm SZ, Stephansen GB, Lassen JF; SORT OUT II 
Investigators. Comparison of paclitaxel- and sirolimus-eluting 
stents in everyday clinical practice: the SORT OUT II randomized 
trial. JAMA. 2008;299:409-16.
 15. Maeng M, Tilsted HH, Jensen LO, Krusell LR, Kaltoft A, 
Kelbæk H, Villadsen AB, Ravkilde J, Hansen KN, Christiansen EH, 
Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Thuesen L, 
Madsen M, Thayssen P, Sørensen HT, Lassen JF. Differential clini-
cal outcomes after 1 year versus 5 years in a randomised compari-
son of zotarolimus-eluting and sirolimus-eluting coronary stents 
(the SORT OUT III study): a multicentre, open-label, randomised 
superiority trial. Lancet. 2014;383:2047-56.
 16. Antonsen L, Thayssen P, Hansen H, Maeng M, Tilsted HH, 
Bøtker HE, Ravkilde J, Madsen M, Sørensen HT, Thuesen L, 
Lassen JF, Jensen LO. Outcomes after revascularisation with 
everolimus- and sirolimus-eluting stents in patients with acute cor-
onary syndromes and stable angina pectoris: a substudy of the 
SORT OUT IV trial. EuroIntervention. 2014;10:212-23.
 17. Thuesen L, Jensen LO, Tilsted HH, Mæng M, Terkelsen C, 
Thayssen P, Ravkilde J, Christiansen EH, Bøtker HE, Madsen M, 
Lassen JF. Event detection using population-based health care data-
bases in randomized clinical trials: a novel research tool in inter-
ventional cardiology. Clin Epidemiol. 2013;5:357-61.
 18. Stefanini GG, Windecker S. Stent performance: never too late 
to sort it out. Lancet. 2014;383:2024-6.
 19. Chawla NV, Davis DA. Bringing big data to personalized 
healthcare: a patient-centered framework. J Gen Intern Med. 
2013;28:S660-5.
 20. Sen H, Tandjung K, Basalus MW, Löwik MM, van 
Houwelingen GK, Stoel MG, Louwerenburg HW, de Man FH, 
Linssen GC, Nijhuis R, Nienhuis MB, Verhorst PM, van der Palen J, 
von Birgelen C. Comparison of eligible non-enrolled patients and 
the randomised TWENTE trial population treated with Resolute 
and Xience V drug-eluting stents. EuroIntervention. 2012;8: 
664-71.
 21. Tandjung K, Sen H, Lam MK, Basalus MW, Louwerenburg JH, 
Stoel MG, van Houwelingen KG, de Man FH, Linssen GC, 
Saïd SA, Nienhuis MB, Löwik MM, Verhorst PM, van der Palen J, 
von Birgelen C. Clinical outcome following stringent discontinu-
ation of dual antiplatelet therapy after 12 months in real-world 
patients treated with second-generation zotarolimus-eluting reso-
lute and everolimus-eluting Xience V stents. 2-year follow-up of 
the randomized TWENTE trial. J Am Coll Cardiol. 2013;61: 
2406-16.
Supplementary data
Online Table 1. Preferred mode and frequency of follow-up assess-
ment questionnaire.
Online Table 2. Preference regarding follow-up assessment in all
responders, and in gender and age-based groups.
9E
uroIntervention 2
0
1
5
;1
1
-online publish-ahead-of-print O
ctober 2
0
1
5
PAPAYA: patient preference regarding follow-up
Supplementary data
Online table 1. Preferred mode and frequency of follow-up 
assessment questionnaire.
1. Please state which type of approach do you feel is acceptable 
for collecting follow-up information after your treatment? 
(Multiple answers allowed)
£ Postal questionnaires
£ Telephone contact
£ E-mail contact
2. Please indicate which type of approach you prefer the most. 
(Please state only 1 answer)
£ Postal questionnaires
£ Telephone contact
£ E-mail contact
£ No preference
3. Please indicate which type of approach you prefer the least.  
(A maximum of 2 options is allowed)
£ Postal questionnaires
£ Telephone contact
£ E-mail contact
4. In case you would prefer telephone contact for collecting 
follow-up information after your treatment, which time of day 
do you prefer to be contacted? 
£ Morning
£ Afternoon
£ Evening
5. Please indicate how many follow-up assessments per year you 
would prefer, after your treatment? (Please state only 1 answer)
£ 0 times per year*
£ 1 time per year
£ 2 times per year
£ 3 times per year
£ 4 times per year
* I would prefer not to be approached for follow-up information, 
but I would allow my doctor/clinical researcher to use the 
information available in my medical files, from my general-
practitioner or pharmacy. 
6. In case you stated postal questionnaires or e-mail as your 
preferred mode of follow-up, how many questions do you feel 
are acceptable? (Please state only 1 answer)
£ ≤5 questions
£ 6-10 questions
£ 11-15 questions
£ >15 questions
7. In case you stated telephone contact as your preferred mode of 
follow-up, how many questions do you feel are acceptable? 
(Please state only 1 answer)
£ ≤5 questions
£ 6-10 questions
£ 11-15 questions
£ >15 questions
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Online Table 2. Preference regarding follow
-up assessm
ent in all responders, and in gender and age-based groups.
≤60 yrs
61-67 yrs
68-75 yrs
>75 yrs
All 
(n=417)
M
en 
(n=352)
W
om
en 
(n=65)
p-value
All 
(n=457)
M
en 
(n=352)
W
om
en 
(n=105)
p-value
All 
(n=531)
M
en 
(n=385)
W
om
en 
(n=146)
p-value
All 
(n=381)
M
en 
(n=242)
W
om
en 
(n=139)
p-value
Preferred approach
0.83
0.03
0.07
0.07
Questionnaire
265 (63.5)
225 (63.9)
40 (61.5)
305 (66.7)
227 (64.5)
78 (74.3)
387 (72.9)
276 (71.7)
111 (76.0)
291 (76.4)
188 (77.7)
103 (74.1)
Telephone
42 (10.1)
34 (9.7)
8 (12.3)
53 (11.6)
37 (10.5)
16 (15.2)
80 (15.1)
57 (14.8)
23 (15.8)
65 (17.1)
37 (15.3)
28 (20.1)
E-m
ail
88 (21.1)
76 (21.6)
12 (18.5)
78 (17.1)
70 (19.9)
8 (7.6)
49 (9.2)
43 (11.2)
6 (4.1)
12 (3.1)
11 (4.5)
1 (0.7)
No preference
22 (5.3)
17 (4.8)
5 (7.7)
21 (4.6)
18 (5.1)
3 (2.9)
15 (2.8)
9 (2.3)
6 (4.1)
13 (3.4)
6 (2.5)
7 (5.0)
Least preferred approach*
0.26
<
0.01
0.02
0.56
Questionnaire
45 (9.3)
37 (9.2)
8 (9.8)
44 (7.4)
36 (8.1)
8 (5.4)
75 (9.6)
54 (9.8)
21 (9.0)
41 (7.1)
24 (6.6)
17 (8.0)
Telephone
299 (61.8)
253 (62.9)
46 (56.1)
305 (51.4)
243 (54.6)
62 (41.9)
339 (43.3)
248 (45.1)
91 (39.1)
210 (36.4)
139 (38.1)
71 (33.5)
E-m
ail
140 (28.9)
112 (27.9)
28 (34.1)
244 (41.1)
166 (37.3)
78 (52.7)
369 (47.1)
248 (45.1)
121 (51.9)
326 (56.5)
202 (55.3)
124 (58.5)
Preferred num
ber of questions 
per contact
0.44
0.05
0.67
0.89
0
0 (0)
0 (0)
0 (0)
1 (0.2)
1 (0.3)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
<
5
16 (3.9)
12 (3.4)
4 (6.5)
48 (10.7)
31 (9.0)
17 (16.5)
84 (16.2)
55 (14.5)
29 (20.7)
89 (24.5)
57 (24.1)
32 (25.4)
6-10
211 (51.3)
176 (50.4)
35 (56.5)
246 (54.8)
185 (53.5)
61 (59.2)
305 (58.8)
219 (57.8)
86 (61.4)
202 (55.6)
131 (55.3)
71 (56.3)
11-15
113 (27.5)
98 (28.1)
15 (24.2)
86 (19.2)
74 (21.4)
12 (11.7)
72 (13.9)
60 (15.8)
12 (8.6)
34 (9.4)
22 (9.3)
12 (34)
>
15
71 (17.3)
63 (18.1)
8 (12.9)
68 (15.1)
55 (15.9)
13 (12.6)
58 (11.2)
45 (11.9)
13 (9.3)
38 (10.5)
27 (11.4)
11 (8.7)
Preferred num
ber of annual 
follow-up events
0.95
0.77
0.30
0.17
0x ¶
10 (2.4)
9 (2.6)
1 (1.5)
27 (6.0)
23 (6.7)
4 (3.9)
47 (9.1)
29 (7.7)
18 (12.9)
45 (12.6)
28 (12.4)
17 (12.9)
1x
222 (53.6)
185 (53.0)
37 (56.9)
257 (57.4)
193 (55.9)
64 (62.1)
332 (64.2)
243 (64.5)
89 (63.6)
213 (59.5)
127 (56.2)
86 (65.2)
2x
137 (33.1)
117 (33.5)
20 (30.8)
127 (28.3)
100 (29.0)
27 (26.2)
112 (21.7)
84 (22.3)
28 (20.0)
88 (24.6)
64 (28.3)
24 (18.2)
3x
10 (2.4)
8 (2.3)
2 (3.1)
13 (2.9)
10 (2.9)
3 (2.9)
6 (1.2)
4 (1.1)
2 (1.4)
5 (1.4)
4 (1.8)
1 (0.8)
4x
35 (8.5)
30 (8.6)
5 (15.7)
24 (5.4)
19 (5.5)
5 (4.9)
20 (3.9)
17 (4.5)
3 (2.1)
7 (2.0)
3 (1.3)
4 (3.0)
Values are n (%
). A few patients did not provide answers to all the survey questions. Preferred approach: m
issing <
20; preferred num
ber of questions and preferred num
ber of annual FUP events m
issing 21-60. *Indication of up to two least preferred 
approaches was perm
itted. ¶Patients preferred follow-up data collection from
 healthcare providers and local residents or national registration offices, but not to be contacted them
selves.
